Patents by Inventor Richard J. Bram
Richard J. Bram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368184Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and methods of using these compound for treating diseases such as cancer are also provided.Type: ApplicationFiled: May 28, 2024Publication date: November 7, 2024Applicants: Mayo Foundation for Medical Education and Research, Sanford Burnham Prebys Medical Discovery InstituteInventors: Richard J. Bram, Anthony B. Pinkerton, Eduard Serguienko
-
Patent number: 12030896Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and methods of using these compound for treating diseases such as cancer are also provided.Type: GrantFiled: July 1, 2019Date of Patent: July 9, 2024Assignees: Mayo Foundation for Medical Education and Research, Sanford Burnham Prebys Medical Discovery InstituteInventors: Richard J. Bram, Anthony B. Pinkerton, Eduard Serguienko
-
Publication number: 20210139505Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and methods of using these compound for treating diseases such as cancer are also provided.Type: ApplicationFiled: July 1, 2019Publication date: May 13, 2021Inventors: Richard J. Bram, Anthony B. Pinkerton, Eduard Serguienko
-
Publication number: 20090226473Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: ApplicationFiled: February 7, 2008Publication date: September 10, 2009Applicant: St. Jude Children's Research HospitalInventors: Richard J. Bram, Gotz Von Bulow
-
Patent number: 7355005Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: GrantFiled: December 23, 2005Date of Patent: April 8, 2008Assignee: St. Jude Children's Research HospitalInventors: Richard J. Bram, Gotz Von Bulow
-
Publication number: 20030082173Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: ApplicationFiled: November 12, 2002Publication date: May 1, 2003Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Richard J. Bram, Gotz Von Bulow
-
Patent number: 6500428Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: GrantFiled: February 14, 2001Date of Patent: December 31, 2002Assignee: St. Jude Children's Research HospitalInventors: Richard J. Bram, Gotz Von Bulow
-
Patent number: 6316222Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: GrantFiled: April 12, 1999Date of Patent: November 13, 2001Assignee: St. Jude Children's Research HospitalInventors: Richard J. Bram, Gotz Von Bulow
-
Patent number: 5969102Abstract: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g.Type: GrantFiled: March 3, 1997Date of Patent: October 19, 1999Assignee: St. Jude Children's Research HospitalInventors: Richard J. Bram, Gotz Von Bulow
-
Patent number: 5523227Abstract: DNA and protein compositions are provided for calcium-signal modulating cyclophilin ligand which are shown to act in the calcium-dependent pathway for activation of a number of genes. The DNA composition and proteins may be used in investigating the processes associated with calcium-dependent activation of genes, as well as screening of drugs for interaction with the subject proteins for modulating cell processes, e.g. T-cell activation.Type: GrantFiled: June 17, 1994Date of Patent: June 4, 1996Assignee: The Board of Trustees of the Leland Stanford Junior Univ.Inventors: Richard J. Bram, Gerald R. Crabtree